Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S. This story matters for Finance & Markets readers tracking finance. Reported by marketwatch.com. Read the full original at the source link below.